Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A green box and boring gkp repeating the same moans. This thread has become a joy. Logging off...
The elephant in the room is obviously money...income, earnings!
Nobody seems to want to talk about it, which ultimately, is the definition of the `elephant in the room` phrase!
Why doesn`t anybody start a thread titled `Finances`?...Its important!
Have they got enough to keep funding R&D before the coin starts rolling in.
Will they need another placing...at, say 170p?
Discuss!
Bottmzup “ spectrum analysis of starboggled countersunk flange gussets!”
Assume this is one of your proprietary charting techniques? One of the many that’s so successful you come on a bb of strangers to tell them what a wolf of wall at you are.
The only flange round here is you. Give it a rest
Bumzup: why do you expect anyone to answer any of your points, when you simply ignore points made to you?
Bottomzup, your last couple of posts have been nothing but deliberate attempts to disrupt, discredit and generally insult other posters. Yet when you get justifiably obtuse responses, you are the first to cry foul, say you are being 'abused' and reach for the report button to admin. You hand it out but can't take it. You relish doing all the things you criticise others for. What a low way of going through life.
I have never reported or filtered anyone on these BB's in over a decade of being a member. Go on . . . make my day.
Err, no they're not. "After all, thats why you`re all here...isn`t it?"
Gkb, twice you've said things and I've counterargued them and you've then agreed with me by saying you are aware of them and gone off on a sideways tangent? You said DeepVerge only used Aptamers and then knew that they also used Affimers?
If in doubt just take a look at the Innova instructions, the directions show you to brain-tickle.
P.S. Five trading days until May, how exciting to know we have the best product (also accounting for all variables including cost, ease of manufacturing, s/s, collection method etc.) coming to market that has a near limitless requirement for these tests. Also about to cement Affimers as a fantastic working tech, lock-in a place in future diagnostic approaches to pandemics and whilst we're at it, globally advertise them/the company too. Think about the money and resource companies like Roche have, and this test has proven itself to blow theirs out of the water!
My research tells me it is. Based on what is currently available on the market/or clinically validated.
As a benchmark, use the PD approved list and review the data and sample method for each test and compare with Avacta’s. That’s what I’ve done on a geeky spreadsheet. Do the same and conclude what you deem appropriate.
AS has provided MUCH more info than any other test currently on the market. He’s lifted the bonnet on its development and people still aren’t happy. Every test of concern has contradictory performance data, and is being used in use cases outside of their design.
It’s a good point retireby40 and one to make clear. The fact it said CE mark for at home use was in the pipeline doesn’t mean the govt couldn’t give it EUA for at home use in the same way they did Innova. After all it’s better on all fronts (bar price which I think may be the current sticking point with HMG)
Gkb, more moaning. Will we be able to sell? The 20 distributors covering 25 European territories suggests yes. As for comparing performance, what do you think the CV is for? Find another AN test with better performance and let us all know... twat
Have you seen the Innova test? So many fiddly parts to it and it was launched for professional use only but was granted EUA for home use. Given the avacta test is both easier to use (fewer parts so much smaller instruction leaflet) and easier to administer given it’s not targeting tonsils and upper part of nasal cavity I suspect we will also get EUA for home use. If not I suspect many of us will lobby gov and even the Good Law Project as our test is also more accurate so I can’t see it not being granted EUA for home use as a precedent is there. To be honest even if not for a while we will sell all we can produce as stated by the CEO.
Nope haven’t a clue bottomzup - O wise one, could you point me in the direction of where to find the SP? Tricky thing to locate.
While you’re at it whats todays tea leaf inverted backwards 8ewa rotated doji candle saying?
Patronising tit
Oh, & the share price. 2.40, around 4 x my original purchase price.
Gkb.
https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/11/C0873_i_SOP_LFD-rollout-for-asymptomatic-staff-testing_phase-2-trusts-v1.1_16-nov20.pdf
Page 3 -" The manufacturer’s instructions for use (IFU) are included in the box and are detailed and very technical. These do not need to be followed as NHS staff will use the test in a slightly different way, which has been agreed with experts, discussed with MHRA, and the manufacturer informed. This is particularly in relation to use of the test for asymptomatic people, self-administration of the test, and the use of nasal swab inside the lower part of both nostrils. The rest of the process (ie the way the test is performed, and the results are interpreted) is the same as set out in the manufacturer’s instructions"
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/943187/S0925_Innova_Lateral_Flow_SARS-CoV-2_Antigen_test_accuracy.pdf
48.89% sensitivity. Yuck
This test comparison thing has been done to death. They’re either NP Mid-T sample designs. Of course they’re not going to state what they’re NOT designed for.
There’s plenty of evidence, to show these tests have a huge performance drop off when used against their use case.
Stop comparing their performance. Absolutely compare their revenue and place on a HMG list. Quite correct.
Rightly or wrongly, Avacta have the highest performing AN test for infectious monitoring. This is fact. Let’s see if this asset sells and overtakes the current market. This is yet to play out. Hence why were investing, and not buying the future.
Again... the Deepverge test is owned by them, the contract was to supply affimers if they want some, so there's nothing to report at all and never will be, so head over and moan on their board.
Followed by more repeated moaning. You're not changing anything by repeating the same whinges...
gkb I think around half of the 17 are Chinese, hopefully they pick one of those if not ours eh ;)
failing that more INNOVA!!!
Hi gkb, DeepVerges test utilises both Aptamers and Affimers in collaboration.
In regard to DHSC home testing of Innova, Innova was validated as a brain-tickler - there are lots of reports out there showing how when used as AN (as AVCT are utilising) the S/S is significantly less than reported. It was designed and tested as a brain-tickler, UK Gov wanted to keep the quantity high so took the decision to allow a very ineffective test, within its unverified collection method, to be utilised. There is a higher quantity of the viral load in the brain-tickler region than there is AP, wouldn't surprise me if we saw 100%/100% s/s with AVCT using that testing method and then passing it through underhand as AP.
I am of the opinion that the top performance of antigen LFTs so far based solely on materials etc has been achieved, i.e. the best combinations have been refined. With the only bottleneck in performance left being the reagent.
What's (actually) funny is Novacyt holders berating antigen LFT stocks for having tests they denounced regularly as harmful and utterly ridiculous vs PCR and then need an antigen LFT themselves to get themselves out of a hole. Given Novacyt have no innate advantages of developing an antigen LFT themselves, knowing the partner is key to determining what sort of quality test it would be. Novacyt management does seem better than most (not including Alistair fyi) so I expect them to expect it to be at least be better than the current crop of antigen LFTs ex Avacta to even attempt to sell.
The application to the antigen LFT of the 'detect all variants' rhetoric Novacyt have adopted is topical but most LFTs would detect all variants so not exactly a USP. To what degree they are affected by variants is the real question. But I would have thought Novacyt would be boasting about having a very sensitive and specific LFT instead. Perhaps nothing spectacular in terms of quality, just another product to get shareholders off their back about what the **** they're going to do after Covid.
@GKB47
Regarding the saliva, worth listening to what he said yesterday. It works but has been put to one side due to Gov and end point users eventually having problems with saliva, due to what you've drank or eaten. Remember the foreign MPs putting a can of coke on a test strip and it coming back positive? Too much contamination for saliva to work in a real life setting. He also said that since it works they can use it for other uses rather than covid (more to come). There has been lots of published documents in recent months saying how unreliable saliva is as a sample method anyway, so nasal is the best.
Regarding the breath test, thats not our test, its just our affimers in it. DVRG have said it works excellently and the affimers are brilliant. However they need to change things like the size of the machine they were planning on using to make it more consumer friendly. The CEO has also hinted massively that its undergoing PD validation.
Regarding validating against other tests, that will come in due course. But you also have to remember that Innova is a brain tickler and a throat swab, how many people will correctly do it? Theres been papers published saying could be as low as 40% on the S/S, very high user error rate. Anterior nasal will be much more user friendly.
British made, Gov get a good media hype with UK jobs being created, money staying inside the UK, tax the companies, so get money back from it. Massive win win situation.
Totally agree with you gkp, they changed tact and now they ‘are’ going to make a shed load of money from the AN LFT enough to ‘hopefully’ fully fund the oncology for the foreseeable.
Hence I swallowed my hubris picked up my teddy and bought more shares.
Trek
I've not sold AVCT but I have moved some funds from other stocks in to NCYT this morning, there's no harm in diversifying and there is plenty of market out there for both!
Sell up, but some NCYT and F off then
Mark.
You can bleat as much as you like, but who here can help you if you listened to and watched the presentation yesterday and completely failed to understand it?